Background. Tedizolid (TED) is a newly-approved oxazolidinone antibiotic that may be better tolerated than linezolid; however, real-world clinical data are limited, particularly among patients receiving prolonged treatment courses. Our objective was to review our clinical experience with TED and describe rates of adverse events.
Background. Cefoxitin has a good in vitro activity and stability in resistance to hydrolysis by ESBLs, and is a good candidate for the treatment of urinary tract infection (UTI). However, data are scarce regarding its use in clinical practice, especially against K. pneumoniae deemed to be capable of the acquirement of porin-deficient mutant.
Methods. We conducted a retrospective study from September 2014 to November 2017, in a tertiary-care hospital. We gathered all prescriptions of Cefoxitin for UTI due to ESBL isolates. We compared the clinical outcomes between E. coli and K. pneumoniae ESBL-producing isolates after a 90-day follow-up. When available, we assessed whether Cefoxitin-based regimen was associated with an emergence of resistance. To our knowledge there is no clinical data supporting a real threat of development of resistance in UTI.
Results. The treatment of 31 patients with a mean age of 60 ± 18 years was analyzed. We observed a clinical cure at D90 in 81.2% (n = 13/16) of cases for ESBL E. coli isolates and 85.7% (12/14) for ESBL K. pneumoniae (P = 0.72). Overall, we noted an efficacy of FOX around 83.3% (n = 25/30).
Median dose of Cefoxitin was 4 g (2-8). Only one patient infected by an ESBL E. coli received an oral relay with levofloxacin for 4 additional days. No adverse events were reported. One patient who relapsed, carried a K. pneumoniae isolate that became intermediate to Cefoxitin in the follow-up.
Conclusion. In a period of major threat with a continuous increase of ESBL obliging to a policy of carbapenem-sparing regimens, it seems detrimental to deprive physicians of using Cefoxitin for ESBL Enterobacteriaceae for the treatment of UTI while our data show its efficacy.
Disclosures. Methods. Retrospective analysis of children who received TOL/TAZ while hospitalized from 2014 to 2017. Clinical and microbiological outcomes and safety data were analyzed.
Results. 8 children received TOL/TAZ for CR-PA infections (table) : 3 cystic fibrosis (CF) exacerbations, 2 ventilator-associated pneumonia (VAP), 1 tracheitis, 1 chronic osteomyelitis (OM), 1 complicated intra-abdominal infection with urinary tract infection (cIAI/cUTI). All initial isolates were susceptible to TOL/TAZ per E-test. Creatinine clearance (CrCl) >90 mL/minute in all patients. Median total length of stay (LOS) was 73 days (d) (range 11-221) and median inpatient duration of TOL/TAZ was 13.5 d (range 5-61). One patient died from causes unrelated to infection; all other patients achieved clinical cure and TOL/TAZ was well tolerated. One patient experienced a slight increase in liver function tests that required dose reduction. 3 children received multiple courses (range: 2-8) for CF exacerbations. TOL/TAZ-resistant PA was detected in 1 patient after 2 months of therapy for OM. TOL/TAZ intermediately susceptible PA was detected in 1 patient after 7 courses of therapy for CF exacerbation, though subsequent cultures grew TOL/TAZ susceptible PA.
Conclusion. TOL/TAZ was effective in treating various CR-PA infections. Therapy was well tolerated with no significant adverse events. Reduced TOL/TAZ susceptibility after prolonged or repeated courses was observed and presents potential opportunities for dose optimization and antimicrobial stewardship. Methods. We conducted a retrospective review of clinical samples with positive cultures for Nocardia spp. from 2011 to 2017. Specimens were cultured in MGIT broth or on Middlebrook agar biplates and isolated colony growth was then identified using MALDI-TOF MS or 16S rDNA gene sequencing. Antimicrobial susceptibility testing was performed using the TREK Sensititre Rapid Growing Mycobacteria Plate.
Results. We reviewed total of 1,840 samples positive for Nocardia spp. Most commonly isolated species included N. cyriacigeorgica (16.9%), N. nova complex (15.7%), N. farcinica complex (14.8%), N. brasiliensis (11.5%) and N. abscessus complex (8.2%). Susceptibilities of the more common Nocardia species are shown in the graph. Source of the positive cultures was variable with majority (>60%) from pulmonary source (sputum, BAL and lung tissue), blood in 5.7% and brain in 3.6%. Most common Nocardia species isolated from brain specimens were N. farcinica complex (24/59) followed by N. abscessus complex (17/59). Most common Nocardia species isolated from blood were N. farcinica complex (38/99) followed by N. nova complex (22/99) and N. cyriacigeorgica (15/99).
Conclusion. The antimicrobials that continue to show high activity against most Nocardia species (>95%) are: amikacin, linezolid and TMP/SMX. N. pseudobrasiliensis was noted to have high rates of resistance to TMP/SMX (87%). N. farcinia, N. brasiliensis and N. transvalensis/wallacei complex were >90% susceptible to amoxicillin/ clavulanate. Clarithromycin had >99% activity against N. nova complex while both ceftriaxone and doxycycline had> 90% activity against N. abscessus complex. It is crucial to identify Nocardia species and obtain susceptibilities to help better choose the regimen with the best clinical outcome. October 6, 2018: 12:30 PM Background. Stenotrophomonas maltophilia is an opportunistic pathogen observed in nosocomial infections. Due to biofilm production and intrinsic resistance to numerous antimicrobials, organism eradication is difficult and morbidity and mortality remain high. Unfortunately, study outcomes are often confounded by co-infecting organisms. Therefore, clinical and microbiologic outcome data for monomicrobial infections is warranted.
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Clinical and Microbiologic Outcomes Among Patients With Monomicrobial
Methods. Single-center, retrospective chart review of adult patients receiving treatment for S. maltophilia between January 2012 and October 2016. Polymicrobial infections and cystic fibrosis patients were excluded. Primary endpoint was clinical cure (CC) at end of therapy. Secondary endpoints included microbiological eradication (ME), 28-day mortality, and resistance selection. An exploratory analysis was performed in patients receiving trimethoprim-sulfamethoxazole (TMP/SMX) or levofloxacin (LVX).
Results. Seventy-six patients were included in the analysis. The population was 60 years of age, predominantly female (62%) with median APACHE score of 16. Infection onset occurred 6 days after admission with 71% located in the ICU. Approximately 2/third of ICU patients were intubated. Primary site of infection was the lung (92%). Treatment strategies included TMP/SMX (45 patients) or LVX (31 patients). Overall, CC, ME, and 28-day mortality was observed in 79%, 82%, and 14%, respectively. Adverse events were uncommon with three patients receiving TMP/SMX requiring alternate therapy. Comparative analysis revealed similar baseline characteristics except higher APACHE scores (18 vs. 14; P = 0.03) and frequency of mechanical ventilation in the TMP/SMX group (64% vs. 30%; P = 0.007). CC was similar between TMP/SMX and LVX (82% vs. 74%, respectively (P = 0.4)). ME was observed in 84% and 77%, respectively (P = 0.5). Resistance selection to primary treatment was observed in 29% (2/7) and 86% (6/7), respectively (P = 0.1).
Conclusion. Use of TMP/SMX or LVX for S. maltophilia infections resulted in high CC rates. No differences in primary or secondary outcomes were observed; however, a trend toward resistance selection with LVX was identified. Larger studies assessing outcomes and resistance selection are warranted to further delineate treatment.
Disclosures. K. Klinker, Melinta Therapeutics: Consultant, Speaker honorarium. Nabriva Therapeutics: Scientific Advisor, Consulting fee. Methods. We performed a retrospective study of ceftaroline-associated neutropenia within a large healthcare system and a comprehensive systematic review of the English literature (2010-2017) of published cases containing individualized case data to describe the incidence, risk factors, and outcomes associated with ceftaroline-associated neutropenia. Neutropenia was defined as an absolute neutrophil count (ANC) of <1,500 cells/mm 3 . Cases with pre-existing neutropenia or other potential reason for the development neutropenia while on ceftaroline were excluded.
Ceftaroline-Associated
Results. A total of 37 cases of ceftaroline-associated neutropenia have been published. The median patient age was 44 years (range 20-90), 22 (59%) were female, and most were receiving ceftaroline for invasive Staphylococcus aureus infections. The median time from ceftaroline initiation to development of neutropenia was at 25 days (range 8-125 days). Agranulocytosis (ANC nadir <100 cells/mm 3 ) developed in 49% of cases (n = 18) and an ANC nadir of 0 in 27% (n = 10). The median duration of neutropenia was an average of 4 days (range 1-16 days). Eleven (30%) received granulocyte-colony stimulating factor (G-CSF) treatment and ceftaroline was discontinued in all cases. The outcome was favorable in all cases, and only one case developed a secondary infection during neutropenia. Literature review of studies containing cases and controls (patients receiving drug but did not develop neutropenia) found an incidence of neutropenia of 12% (range 7-18% per individual study) when ceftaroline was utilized for ≥7-14 days, higher than for comparator antibiotics in the literature. Risk factors for the development of neutropenia during ceftaroline varied between studies and remains undefined.
Conclusion. Neutropenia is common when ceftaroline is utilized for ≥14 days and close hematologic monitoring is warranted. Further research is needed to determine the mechanism and risk factors for the high incidence of neutropenia associated with long-term ceftaroline use.
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